{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:10:08Z","timestamp":1787062208919,"version":"build-2736575974"},"reference-count":26,"publisher":"American Society of Hematology","issue":"1","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Bone marrow microenvironment plays an important role in promoting growth and survival of multiple myeloma (MM) cells. The tumor-promoting immune microenvironment is augmented while antitumor immune responses are inhibited. Although clinical and genomic markers of high-risk MM have been described, the immune status is just being recognized as a potential mediator of disease behavior. This is even more important with the development of a number of immune-based therapies. Based on these considerations, we evaluated peripheral blood absolute lymphocyte count (ALC) as an easily accessible marker representing immune microenvironment at diagnosis and after treatment of MM. We retrospectively evaluated 11\u2009427 patients diagnosed with MM between 2000 and 2019 at Veterans Administration hospitals using ALC obtained closest to diagnosis and up to 2.5 years thereafter. Patients were stratified into 3 ALC categories: severely low, low, and normal (&amp;lt;1\u00a0\u00d7 103\/\u03bcL, 1\u00a0\u00d7 103\/\u03bcL to 1.5\u00a0\u00d7 103\/\u03bcL, and &amp;gt;1.5\u00a0\u00d7 103\/\u03bcL, respectively). Lymphopenia (including severely low and low ALC) was present in 53% of patients at MM diagnosis and was associated with inferior overall survival (OS). The median OS for patients with severely low, low, and normal ALC at diagnosis was 2.7, 3.3, and 4.2 years (P\u00a0&amp;lt; .001), respectively. Moreover, persistent or new development of lymphopenia during treatment and follow-up was also associated with inferior OS. Our findings support the use of ALC as a biomarker for risk stratification in MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014125","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T17:37:28Z","timestamp":1730223448000},"page":"78-88","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9377-9129","authenticated-orcid":false,"given":"Grace M.","family":"Ferri","sequence":"first","affiliation":[{"name":"1Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cenk","family":"Yildirim","sequence":"additional","affiliation":[{"name":"2Cooperative Studies Program Informatics Center, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6868-7011","authenticated-orcid":false,"given":"Nhan V.","family":"Do","sequence":"additional","affiliation":[{"name":"1Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, MA"},{"name":"2Cooperative Studies Program Informatics Center, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA"},{"name":"3Section of Hematology, Veterans Administration Boston Healthcare System, West Roxbury, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Brophy","sequence":"additional","affiliation":[{"name":"1Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, MA"},{"name":"2Cooperative Studies Program Informatics Center, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA"},{"name":"3Section of Hematology, Veterans Administration Boston Healthcare System, West Roxbury, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Park","sequence":"additional","affiliation":[{"name":"4Jerome Lipper Multiple Myeloma Center, Division of Plasma Cell Neoplasias, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"5Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"3Section of Hematology, Veterans Administration Boston Healthcare System, West Roxbury, MA"},{"name":"4Jerome Lipper Multiple Myeloma Center, Division of Plasma Cell Neoplasias, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8058-3423","authenticated-orcid":false,"given":"Nathanael R.","family":"Fillmore","sequence":"additional","affiliation":[{"name":"2Cooperative Studies Program Informatics Center, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA"},{"name":"4Jerome Lipper Multiple Myeloma Center, Division of Plasma Cell Neoplasias, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2601-0667","authenticated-orcid":false,"given":"Camille V.","family":"Edwards","sequence":"additional","affiliation":[{"name":"6Section of Hematology and Oncology, Department of Medicine, Boston Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"issue":"2","key":"2025011416261295300_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","article-title":"Tolerance and exhaustion: defining mechanisms of T cell dysfunction","volume":"35","author":"Schietinger","year":"2014","journal-title":"Trends Immunol"},{"issue":"4","key":"2025011416261295300_bib2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF00916554","article-title":"Selective loss of CD4+ CD45R+ T cells in peripheral blood of multiple myeloma patients","volume":"8","author":"Serra","year":"1988","journal-title":"J\u00a0Clin Immunol"},{"issue":"1","key":"2025011416261295300_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0889-8588(05)70415-9","article-title":"Immunoregulatory mechanisms in multiple myeloma","volume":"11","author":"Munshi","year":"1997","journal-title":"Hematol Oncol Clin N Am"},{"issue":"26","key":"2025011416261295300_bib4","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","article-title":"Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma","volume":"115","author":"Prabhala","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2025011416261295300_bib5","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.3109\/10428194.2014.904511","article-title":"Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma","volume":"55","author":"Favaloro","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"2025011416261295300_bib6","first-page":"198539","article-title":"Immunological dysregulation in multiple myeloma microenvironment","author":"Romano","year":"2014","journal-title":"BioMed Res Int"},{"issue":"5","key":"2025011416261295300_bib7","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12185-023-03579-x","article-title":"Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy","volume":"117","author":"Russell","year":"2023","journal-title":"Int J Hematol"},{"issue":"1","key":"2025011416261295300_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood.V98.1.23","article-title":"Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients","volume":"98","author":"Kay","year":"2001","journal-title":"Blood"},{"issue":"2","key":"2025011416261295300_bib9","first-page":"556","article-title":"Increased numbers of T helper 17 cells and the correlation with clinicopathological characteristics in multiple myeloma","volume":"40","author":"Shen","year":"2012","journal-title":"J\u00a0Int Med Res"},{"issue":"18","key":"2025011416261295300_bib10","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2010-05-283895","article-title":"A\u00a0novel role of IL-17\u2013producing lymphocytes in mediating lytic bone disease in multiple myeloma","volume":"116","author":"Noonan","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2025011416261295300_bib11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.clml.2019.12.009","article-title":"A\u00a0unique role of T helper 17 cells in different treatment stages of multiple myeloma","volume":"20","author":"Ma","year":"2020","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"1","key":"2025011416261295300_bib12","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/blood.V90.1.340.340_340_345","article-title":"Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial","volume":"90","author":"Kay","year":"1997","journal-title":"Blood"},{"issue":"3","key":"2025011416261295300_bib13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1046\/j.1365-2141.1998.00609.x","article-title":"T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486\/E3A93","volume":"100","author":"Kay","year":"1998","journal-title":"Br J Haematol"},{"issue":"26","key":"2025011416261295300_bib14","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025011416261295300_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood.2019004309","article-title":"Risk factors in multiple myeloma: is it time for a revision?","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2025011416261295300_bib16","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/bloodadvances.2022008021","article-title":"Peripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma","volume":"7","author":"Edwards","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"2025011416261295300_bib17","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00277-013-1978-8","article-title":"Predicting survival for multiple myeloma patients using baseline neutrophil\/lymphocyte ratio","volume":"93","author":"Kelkitli","year":"2014","journal-title":"Ann Hematol"},{"issue":"11","key":"2025011416261295300_bib18","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00277-015-2462-4","article-title":"Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents","volume":"94","author":"Romano","year":"2015","journal-title":"Ann Hematol"},{"issue":"12","key":"2025011416261295300_bib19","doi-asserted-by":"crossref","first-page":"18792","DOI":"10.18632\/oncotarget.13320","article-title":"Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma","volume":"8","author":"Shi","year":"2017","journal-title":"Oncotarget"},{"issue":"17","key":"2025011416261295300_bib20","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2010-04-279893","article-title":"Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma","volume":"116","author":"G\u00f6rg\u00fcn","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2025011416261295300_bib21","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood.V118.21.1838.1838","article-title":"Proteasome inhibitors sensitize myeloma cells to T cell-mediated killing","volume":"118","author":"van de Donk","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2025011416261295300_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-022-00633-5","article-title":"Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study","volume":"12","author":"Dong","year":"2022","journal-title":"Blood Cancer J"},{"issue":"24","key":"2025011416261295300_bib23","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.2019000406","article-title":"With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study","volume":"133","author":"Fillmore","year":"2019","journal-title":"Blood"},{"key":"2025011416261295300_bib24","doi-asserted-by":"crossref","first-page":"575168","DOI":"10.3389\/fonc.2020.575168","article-title":"Real world experience of daratumumab: evaluating lymphopenia and adverse events in multiple myeloma patients","volume":"10","author":"Cottini","year":"2020","journal-title":"Front Oncol"},{"issue":"3","key":"2025011416261295300_bib25","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood-2005-02-0456","article-title":"IL-6 blocks a discrete early step in lymphopoiesis","volume":"106","author":"Maeda","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2025011416261295300_bib26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jlb.45.2.155","article-title":"Mechanisms of tumor necrosis factor alpha-induced lymphopenia, neutropenia, and biphasic neutrophilia: a study of lymphocyte recirculation and hematologic interactions of TNF alpha with endogenous mediators of leukocyte trafficking","volume":"45","author":"Ulich","year":"1989","journal-title":"J\u00a0Leukoc Biol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/1\/78\/2349813\/blooda_adv-2024-014125-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/1\/78\/2349813\/blooda_adv-2024-014125-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T11:26:30Z","timestamp":1736853990000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/1\/78\/525815\/Lymphopenia-predicts-poor-outcomes-in-newly"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014125","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]}}}